Toxicity of β-Lactam Antibiotics: Pathophysiology, Molecular Biology and Possible Recovery Strategies

Bozcal, Elif; Dagdeviren, Melih

doi:10.5772/intechopen.70199

Cited by 9 publications

(5 citation statements)

References 85 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…β‐lactam antibiotics are a class of antibiotics and have a β‐lactam ring in their molecular structure (Bozcal & Dagdeviren, 2017). They are classified into five groups: penicillins, cephalosporins, carbapenems, penems, and monobactams (Lima et al, 2020).…”

Section: β‐Lactam Antibioticsmentioning

confidence: 99%

β_lactam antibiotics against drug addiction: A novel therapeutic option

Esmaili‐Shahzade‐Ali‐Akbari,

Ghaderi,

Hosseini

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

Drug addiction as a problem for the health of the individual and the society is the result of a complex process in which there is an interaction between brain nuclei and neurotransmitters (such as glutamate). β‐lactam antibiotics, due to their enhancing properties on the glutamate transporter glutamate transporter‐1, can affect and counteract the addictive mechanisms of drugs through the regulation of extracellular glutamate. Since glutamate is a key neurotransmitter in the development of drug addiction, it seems that β‐lactams can be considered as a promising treatment for addiction. However, more research in this field is necessary to identify other mechanisms involved in their effectiveness. This article is a review of the studies conducted on the effect of β‐lactam administration in preventing the development of drug addiction, as well as their possible cellular and molecular mechanisms. This review suggests the clinical use of β‐lactam antibiotics that have weak antimicrobial properties (such as clavulanic acid) in the treatment of drug dependence.

show abstract

Section: β‐Lactam Antibioticsmentioning

confidence: 99%

β_lactam antibiotics against drug addiction: A novel therapeutic option

Esmaili‐Shahzade‐Ali‐Akbari,

Ghaderi,

Hosseini

et al. 2023

Drug Development Research

View full text Add to dashboard Cite

show abstract

“…The negative consequences arising from the prolonged usage of antibiotics are well described in the literature and vary greatly across the different classes of antibiotics. Aminoglycosides are well known to cause nephrotoxicity and ototoxicity, beta-lactams have been linked to triggering allergic reactions [ 8 ], and fluoroquinolones can cause cardiac arrhythmias and QTc prolongation [ 9 ], to name just a few common classes. In addition to direct medication side effects, all antibiotics can disrupt the host microbiome, which leads to an increased risk of Clostridium difficile infection [ 10 ].…”

Section: Introductionmentioning

confidence: 99%

When to Stop Antibiotics in the Critically Ill?

Nielsen,

Dean,

Shald

et al. 2024

Antibiotics

View full text Add to dashboard Cite

Over the past century, antibiotic usage has skyrocketed in the treatment of critically ill patients. There have been increasing calls to establish guidelines for appropriate treatment and durations of antibiosis. Antibiotic treatment, even when appropriately tailored to the patient and infection, is not without cost. Short term risks—hepatic/renal dysfunction, intermediate effects—concomitant superinfections, and long-term risks—potentiating antimicrobial resistance (AMR), are all possible consequences of antimicrobial administration. These risks are increased by longer periods of treatment and unnecessarily broad treatment courses. Recently, the literature has focused on multiple strategies to determine the appropriate duration of antimicrobial therapy. Further, there is a clinical shift to multi-modal approaches to determine the most suitable timepoint at which to end an antibiotic course. An approach utilising biomarker assays and an inter-disciplinary team of pharmacists, nurses, physicians, and microbiologists appears to be the way forward to develop sound clinical decision-making surrounding antibiotic treatment.

show abstract

“…The first β-lactam antibiotic, penicillin G, was developed to treat bacterial infections. As these compounds affect the biosynthesis of the bacterial cell wall and demonstrated high efficiency, there has been an increase in the search, development and production of similar penicillin derivatives ( Drawz and Bonomo 2010 ; Bozcal and Dagdeviren 2017 ; Tooke et al, 2019 ). In particular, the emergence of β-lactamase-mediated resistance can compromise β-lactam antibiotics efficiency.…”

Section: Introductionmentioning

confidence: 99%

Silver(I)-Tazobactam Frameworks with Improved Antimicrobial Activity

et al. 2022

View full text Add to dashboard Cite

Tazobactam (TazoH) is a penicillinate sulfone β-lactamase inhibitor with negligible antimicrobial activity, commonly used with other antibiotics to provide an effective combination against many susceptible organisms expressing β-lactamases. Two novel Ag(I)-tazobactam frameworks ([Ag(I)-Tazo] and [Ag(I)-Tazo2]) prepared by mechanochemistry are presented herein as alternative forms to improve the antimicrobial activity of tazobactam by exploring synergistic effects with silver, being the first crystal structures reported of tazobactam coordinating to a metal site. The topological analysis of the 3D ([Ag(I)-Tazo]) and 2D+1D ([Ag(I)-Tazo2]) frameworks revealed underlying nets with the cbs (CrB self-dual) and decorated sql topologies, respectively. These novel frameworks are stable and show an enhanced antimicrobial activity when compared to tazobactam alone. Amongst the tested microorganisms, Pseudomonas aeruginosa is the most sensitive to tazobactam and the new compounds. This study thus unveils novel facets of tazobactam chemistry and opens up its application as a multifunctional linker for the design of antibiotic coordination frameworks and related materials.

show abstract

Toxicity of β-Lactam Antibiotics: Pathophysiology, Molecular Biology and Possible Recovery Strategies

Cited by 9 publications

References 85 publications

β_lactam antibiotics against drug addiction: A novel therapeutic option

β_lactam antibiotics against drug addiction: A novel therapeutic option

When to Stop Antibiotics in the Critically Ill?

Silver(I)-Tazobactam Frameworks with Improved Antimicrobial Activity

Contact Info

Product

Resources

About